Segment Reporting - Segment information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting
Grant revenue	$ 5,174	$ 4,529
Total research and development expenses	34,426	33,770
Total general and administrative expenses	13,184	11,649
Total operating expenses	47,610	45,419
Operating loss	(42,436)	(40,890)
Other income (expense), net	23,520	(28,155)
Net loss	(18,916)	(69,045)
Single Reportable Segment
Segment Reporting
Grant revenue	5,174	4,529
Expenses not allocated by projects	2,408	3,042
Total external research and development expenses	13,696	14,647
Research and development personnel expenses	10,764	9,408
Other research and development expenses	9,966	9,715
Total research and development expenses	34,426	33,770
General and administrative personnel expenses	4,935	2,480
Other general and administrative expenses	8,249	9,169
Total general and administrative expenses	13,184	11,649
Total operating expenses	47,610	45,419
Operating loss	(42,436)	(40,890)
Other income (expense), net	23,520	(28,155)
Net loss	(18,916)	(69,045)
Single Reportable Segment | AP-PA02: Non-Cystic Fibrosis Bronchiectasis
Segment Reporting
External research and development expenses	6,840	4,922
Single Reportable Segment | AP-PA02: Cystic Fibrosis
Segment Reporting
External research and development expenses	236	1,692
Single Reportable Segment | AP-SA02: Bacteremia
Segment Reporting
External research and development expenses	4,177	4,789
Single Reportable Segment | AP-SA02Prosthetic Joint Infection
Segment Reporting
External research and development expenses	$ 35	$ 202